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Background: Acute kidney injury (AKI) is associated with poor outcome in critically ill children. While data extracted
from retrospective study of pediatric populations demonstrate a high incidence of AKI, the literature lacks focused
and comprehensive multicenter studies describing AKI risk factors, epidemiology, and outcome. Additionally, very
few pediatric studies have examined novel urinary biomarkers outside of the cardiopulmonary bypass population.
Methods/Design: This is a prospective observational study. We anticipate collecting data on over 5000 critically ill
children admitted to 31 pediatric intensive care units (PICUs) across the world during the calendar year of 2014.
Data will be collected for seven days on all children older than 90 days and younger than 25 years without baseline
stage 5 chronic kidney disease, chronic renal replacement therapy, and outside of 90 days of a kidney transplant or
from surgical correction of congenital heart disease. Data to be collected includes demographic information,
admission diagnoses and co-morbidities, and details on fluid and vasoactive resuscitation used. The renal angina
index will be calculated integrating risk factors and early changes in serum creatinine and fluid overload. On days
2–7, all hemodynamic and pertinent laboratory values will be captured focusing on AKI pertinent values. Daily
calculated values will include % fluid overload, fluid corrected creatinine, and KDIGO AKI stage. Urine will be
captured twice daily for biomarker analysis on Days 0–3 of admission. Biomarkers to be measured include
neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP),
and interleukin-18 (IL-18). The primary outcome to be quantified is incidence rate of severe AKI on Day 3 (Day 3 – AKI).
Prediction of Day 3 – AKI by the RAI and after incorporation of biomarkers with RAI will be analyzed.
Discussion: The Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology (AWARE) study,
creates the first prospective international pediatric all cause AKI data warehouse and biologic sample
repository, providing a broad and invaluable resource for critical care nephrologists seeking to study risk
factors, prediction, identification, and treatment options for a disease syndrome with high associated
morbidity affecting a significant proportion of hospitalized children.
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Acute kidney injury (AKI) is associated with poor out-
come in critically ill children. The reported incidence
rate of AKI in children admitted to pediatric intensive
care units (PICUs) range from 8% and 89% [1-6]. AKI
has been associated with prolonged hospital stay, pro-
gression to chronic kidney disease, and a significantly
higher relative risk of in-hospital death [7-10]. The epi-
demiology and outcomes of adult AKI have been vali-
dated through large, multi-center studies describing over
20,000 adult patients [11-13]. Unfortunately, the current
pediatric literature lacks such extensive studies. To date,
the largest study about AKI in children admitted to
PICU was carried by Schneider et al. on 3396 children
[1]. Despite the large population size, this was a single-
center study and also did not use the pediatric RIFLE
criteria to define AKI, the standard for pediatric AKI def-
inition before the recent KDIGO consensus criteria [4,14].
Aside from a few single center studies, most knowledge
of pediatric AKI is gleaned from retrospective studies
with relatively small sample sizes and with diverse AKI
definitions [2,4,15]. To date, there is no multicenter pro-
spective study describing the epidemiology and outcome
of pediatric AKI in PICUs.
Despite increasing awareness of the prevalence and
significance of AKI, effective therapies for this condition
are lacking. This, at least in part, stems from a failure to
recognize AKI before a significant degree of renal dam-
age has already occurred. The inability to diagnose AKI ex-
peditiously follows from the fact that the currently accepted
definitions of AKI rely on changes in serum creatinine
(SCr) and urine output [4]. The well-recognized limitations
of SCr have been previously described [16,17]. Intensive
basic and translational research has targeted the discovery
of biomarkers able to uncover AKI prior to elevations in
serum creatinine. To date, a number of promising candi-
date urinary AKI biomarkers have emerged following pre-
liminary proteomic analyses in murine models of renal
ischemia [18]. Clinical studies indicate that urinary neu-
trophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule-1 (KIM-1), interleukin 18 (IL-18) and
liver-type fatty acid binding protein (L-FABP) all predict
AKI in children following cardiopulmonary bypass prior
to changes in serum creatinine [19-21]. Widespread clin-
ical extrapolation of these results is challenging, however,
given their derivation and validation in homogenous pop-
ulations free from common co-morbidities and exposed
to a uniform insult on a known time scale. New adult-
specific data indicate that plasma NGAL demonstrates
reasonable predictive performance in heterogeneous pa-
tients, with variable comorbidities, presenting to the emer-
gency room [22]. Neither plasma NGAL, nor the other
biomarkers listed above, have demonstrated robust effi-
cacy in children with heterogeneous illness when tested inisolation. Additionally, select early papers utilized defini-
tions of AKI that may have contributed to the high sensi-
tivities subsequently achieved by urinary biomarkers [23].
Such issues may underlie these urinary biomarkers' inabil-
ity to predict AKI severity, identify children who would
require renal replacement therapy (RRT), and predict
AKI-associated death [23-27]. In response to a need of
clinical predictors of AKI, we proposed the renal angina
clinical model [28,29]. In this model, a composite of clin-
ical risk factors and clinical evidence (the renal angina
index (RAI)) of acute kidney injury directs biomarker
testing, akin to directed assessment of troponin I only
in select patients with chest pain. This model seeks a high
negative predictive value (NPV) for AKI of not fulfilling
renal angina. Further, unlike difficult to use, severity of ill-
ness scoring systems which merely score existing injury,
fulfillment of renal angina aids prediction of severe AKI.
In relatively small, retrospective studies, we have demon-
strated that the RAI offers moderate discrimination for
severe AKI, prediction which improves after the in-
corporation of biomarkers [30]. This ‘targeting’ of bio-
marker testing demonstrates a methodology to optimize
the utility of novel diagnostics.
Given the paucity of prospective studies directly aimed
at investigating pediatric AKI in critical illness, a large
and diverse observational study is needed to enrich the
field of pediatric critical care nephrology with current
data. In this manuscript we describe the methodology
of the Assessment of Worldwide AKI, Renal Angina
and Epidemiology (AWARE) study. The AWARE re-
pository will facilitate analysis of epidemiologic trends,
refine risk stratification, solidify associated morbidities,
identify disparities across the globe, and potentially un-




The design is a prospective, multi-center, observational
trial of critically ill children admitted to the pediatric in-
tensive care unit (PICU).
Setting
The setting is 32 PICUs across 5 continents and 12 coun-
tries. Site investigators are listed in Additional file 1.
Population
Eligible participants fulfill all inclusion and no exclusion
criteria.
Inclusion criteria
The inclusion criteria are designed to capture as many po-
tential study patients as possible and are inclusive of most
patients admitted to the PICU and cardiac intensive care
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patients with an ICU length of stay of at least 48 hours are
included in data analysis (other patient data is kept for
demographic data repository, but excluded from data ana-
lysis for renal angina or AKI associated outcome).
1. In-patient in a PICU or CICU
2. Age ≥ 90 days
3. Age < 25 yearsExclusion criteria
1. Maintenance hemodyialysis or peritoneal dialysis.
2. Chronic kidney disease with a baseline estimated
glomerular filtration rate (eGFR) of < 15 ml/min/1.73 m2.
3. Kidney transplant within 90 days of PICU/CICU
admission.
4. Post-operative from surgical correction of cyanotic
congenital heart disease within 90 days of PICU/
CICU admission.
5. Uncorrected congenital heart disease (does NOT
include patients with an isolated atrial or ventricular
septal defect, patent ductus arteriosus, or patent
foramen ovale).
6. Immediately following elective cardiac
catheterization.
For exclusion criteria 4–6, patients admitted and then
taken to the operating theater for surgical corrections
requiring cardiopulmonary bypass are included for
study.Urine collection
For sites that have agreed to collect urine samples, eli-
gible patients for study will have urine collected from an
indwelling urinary catheter (foley) or via clean intermit-
tent catheterization twice daily (between 6 and 10 am
and between 3 and 7 pm) within the first 48 hours of ad-
mission (and then for as many of the regularly scheduled
samples as possible within the first 4 days of PICU/
CICU admission). Patients are not bagged or catheter-
ized separately/independently for the purposes of this
study. Collected urine samples are kept on ice or in 4°C
refrigerator until they are processed. During processing,
specimens are centrifuged at 3000 RPM at 4°C for fifteen
minutes. The supernatants are divided into up to nine
1-mL cryovials depending on the collected urine vol-
ume and stored at minus 80°C. The stored urine samples
from all participating sites are shipped to the Center for
Acute Care Nephrology/Nephrology Center of Excellence
Biomarker Core Laboratory in the Division of Nephrology
and Hypertension at Cincinnati Children’s Hospital
Medical Center.Urinary biomarker sampling
Urine NGAL will be assayed using a human-specific com-
mercially available enzyme-linked immunosorbent assay
(ELISA, AntibodyShop, Grusbakken, Denmark). Urine
IL-18 and L-FABP will be measured using commercially
available ELISA kits (Medical & Biological Laboratories
Co., Nagoya, Japan, and CMIC Co., Tokyo, Japan, respect-
ively) per manufacturer’s instructions. Urine KIM-1 is
measured by ELISA using commercially available reagents
(R&D Systems, Inc., Minneapolis, Minnesota).
Variable collection
Data collected per patient encompasses admission demo-
graphic data, daily morning hemodynamic parameters,
daily laboratory values specific for kidney function, assess-
ments of fluid balance including net fluid in and net fluid
out, and use of nephrotoxins or diuretic agents. For ad-
mission epidemiology, primary ICU diagnoses are broadly
divided into shock/infection/major trauma, medical car-
diac, respiratory failure, post-surgical/minor trauma, central
nervous system dysfunction, and pain/sedation manage-
ment. Net fluid balance is divided into total fluids and urine
flow rates derived per kilogram admission body weight per
hour. Daily calculated values include:
1. Estimated change in creatinine clearance
a. Calculated as percent change of daily creatinine
from baseline creatinine.
b. Baseline creatinine used is lowest consistent
serum creatinine 90 days or more prior to
admission.
c. For patients without a prior baseline, an assumed
creatinine clearance of 120 ml/min/1.73 m2 is
used [3].
2. Percent fluid overload
a. Calculated as previously described [31].
3. Fluid corrected serum creatinine
a. Calculated as previously described [32].
4. KDIGO stage AKI by creatinine
a. Based on KDIGO AKI guidelines [33].
Renal angina index calculation
To ascertain fulfillment or absence of renal angina on
the day of admission, the renal angina index will be cal-
culated as previously described (Additional file 2) [5].
An RAI of ≥8 will be interpreted as fulfillment of renal
angina.
MediData Rave™
Data entry of the variables of interest will be performed
by the investigators and clinical research coordinators
at the participating sites using a web-based data base:
MediData Rave™. Rave™ is a commercial system designed
to capture, manage, and report clinical research data.
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unique code, as identified by the study team. If responses
to the initial inclusion and exclusion criteria provided by
the individual performing the data entry fulfill study cri-
teria, the system will dynamically generate the remainder
of the patient casebook, opening the “gateway” for the site
to enter additional data for an enrolled patient. When eli-
gibility is determined, the system will guide the data entry
personnel at each site to enter the clinical variables of
interest. All participating sites will use the same case re-
port forms (CRFs). The electronic CRFs will be designed
and monitored by the representatives in the Data Manage-
ment Center (DMC) at Cincinnati Children’s Hospital
Medical Center (CCHMC) based on the paper CRFs de-
veloped by the clinical team. The DMC team from the co-
ordinating site, the Center for Acute Care Nephrology
(CACN) at CCHMC, will be the only individuals that can
access and extract the data for all other sites. Other sites
will have access only to their enrolled subjects in Rave™.
Data management and statistical analysis will be executed
at CCHMC.
Interventions
AWARE is a non-intervention observational study.
Urine collection will occur only for patients that have an
indwelling urinary catheter or are scheduled for clean
intermittent catheterization.
Consent
AWARE is proposed as human subjects research with a
waiver of informed consent/parental permission and assent.
This waiver is pursued by the following rationale:
1. The research involves no more than minimal risk to
the subjects.
2. The waiver does not adversely affect the rights and
welfare of the subjects.
3. The research cannot practically be carried out
without the waiver or alteration. Enrolling the
maximum number of PICU admissions during the
study period yields the greatest and most
informative amount of data. Requiring informed
consent from every eligible patient causes a
significant reduction in enrollment and potentially
introduces selection bias into the dataset
(i.e., omission of all patients from centers with limited
clinical research personnel). Robust quality
improvement and process improvement work in
patients with acute kidney injury requires that all
subjects with acute kidney injury be included in
the process. Requiring informed consent leads to
incomplete participation, and therefore the data
gathered under an informed consent requirement
reduces the reliability of the data.4. The research on urine collection and biomarker
measurements is reliably and confidentially
performed with waiver of consent as long as the
following caveats are applied
a. Only urine intended for discard or waste will be
used.
b. Urine will be collected only from patients with an
indwelling urinary drainage system and collection
apparatus or scheduled for intermittent
catheterization. Patients will not be bagged or
catheterized separately/independently for the
purposes of this study.
The sites participating in AWARE have obtained appro-
priate ethical board approval from their respective review
consensus boards (Additional files 3 and 4). No site par-
ticipating in the study is awaiting approval from an ethical
board. Although some institutions have waived the need
for consent, some require written, informed consent and
this will be obtained as indicated to fulfill an additional in-
clusion criterion.
Co-enrollment
Patients enrolled in AWARE may also be enrolled in
other studies without exception. As AWARE is non-
interventional, there is no overlap in the observation
with other CACN or PICU/CICU origin studies.
Primary and secondary outcomes
Our primary outcome is to report the epidemiology and
associated outcomes of pediatric AKI worldwide (in over
30 PICUs, 12 different countries, 5 continents). This out-
come is dependent on broad enrollment from participat-
ing centers. AKI is defined as KDIGO stage 2 or 3 AKI by
creatinine and/or urine output criteria on Day 3 or later of
PICU/CICU admission (Day 3 AKI).
Our secondary outcomes are to validate and refine the
renal angina risk stratification model for prediction of
Day 3 AKI.
1. Determine if fulfillment of renal angina on Day 0 is
predictive of severe AKI on Day 3 of PICU/CICU
admission across the heterogeneous patient
landscape of our participating centers. The AWARE
data repository will be used to validate the precision
of the RAI in ruling out AKI.
2. Determine if prediction of Day 3 AKI by an RAI ≥ 8
is augmented by inclusion of urinary biomarkers
alone or in combination.
Longer term outcomes to be followed include duration
of mechanical ventilation, use of continuous renal re-
placement therapy, use of extracorporeal assist devices
such as extracorporeal membrane oxygenation (ECMO)
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and mortality (Day 30 follow up).
Sample size
The AWARE study will be the largest prospective
pediatric AKI study describing global epidemiology, risk
factors, and associated outcomes. To date, the largest
prospective cohort study of AKI to date was conducted
by the Beginning and Ending Supportive Therapy for the
Kidney (BEST Kidney) investigators [34]. In the BEST
Kidney study 18% of 29,269 patients prospectively stud-
ied after admission to 54 adult ICUs across 23 countries
over 15 months developed AKI. For the AWARE study, we
based our sample size estimation on the number needed
to validate RAI internationally. We validated RAI in 370
PICU admissions from two different sites (average of 185
per site) in North America [5]. To be able to make RAI a
universal index, we need to validate the RAI in all partici-
pating sites. Accordingly we are estimating the average
number of enrolled children to be an average of 150 from
each participating site with a total of approximately 5,250
children from all sites (assuming the final number of par-
ticipating centers is around 35). Among the participating
sites, we estimate one third to participate in urine collec-
tion, resulting in an expected approximately 1750 patients
with urine biomarkers able to be measured. We are allo-
cating each site 3 consecutive months to complete patient
enrollment. Data capture can occur after the three months
are complete, but no new patients are to be enrolled.
Analysis
Analysis of data will be performed independently based
on each specific aim.
1. Data for the primary objective of describing the
epidemiology of AKI will be presented as a
descriptive model. The prevalence on day 0 and
incidence of AKI in up to 7 days of ICU admission
using KDIGO classification will be calculated for
each site cohort to identify the geographical “hot
spots” of pediatric AKI. The data then will be pooled
into a single cohort to study the outcome of AKI.
The whole cohort will be stratified on Day 3 into
four sub-populations with: no AKI, AKI-KDIGO
Stage 1, AKI-KDIGO Stage 2, and AKI-KDIGO
Stage 3. An adjusted and unadjusted survival analysis
models using log rank test and cox regression
models will be used to compare the mortality rates
and the need of renal replacement therapy between
the 4 groups.
2. The prognostic value of the renal angina index will
be calculated on Day 0 for the development of Day 3
AKI. RAI will be evaluated as a diagnostic test and
sensitivity, specificity, positive predictive value,negative predictive value, likelihood ratios, and
receiver operating characteristics (ROCs) will be
derived.
3. Individual prognostic values of each of the four
urinary biomarkers al one for Day 3 AKI will be
calculated. The biomarkers will be tested in
combination for changes in prognostic parameters
and comparisons of discrimination using net
reclassification improvement (NRI) and integrated
discrimination improvement (IDI) will be derived.
Finally, the contribution of each biomarker to the
predictive model of renal angina for Day 3 AKI will
be analyzed by integrating the biomarkers alone and
in combination with the RAI.
Additionally, the association of renal angina index, urin-
ary biomarker levels with clinical outcomes, including
mortality, PICU length of stay, hospital length of stay, and
renal replacement therapy provision, will be assessed using
Chi-square test (or Fisher’s exact test for small counts)
or Pearson correlation coefficient (or non-parametric
Spearman correlation coefficient) based on the nature of
data. Classification and regression tree analysis will be
used to determine optimal decision rules for biomarker
incorporation with RAI when discriminating for Day 3
AKI. In all analyses, a p-value of <0.05 will be considered
statistically significant.
Oversight
The Center for Acute Care Nephrology at CCHMC will
oversee the AWARE trial from start to finish. The cen-
tral data repository through RAVE™ will be housed at
CCHMC. Each site will perform screening, enrollment,
consenting (when applicable), processing the urine sam-
ples (when applicable), collecting and entering data to
Rave™ web browser. The research personnel in every site
will be able to access the data of children enrolled from
the same site. Only CCHMC research personnel will have
access to the data collected for the purposes of this study
from all participating sites. CCHMC will be responsible
for managing and analyzing the data and testing the urine
samples for urinary biomarkers. All participating sites will
use the same case report form (CRF). The web-based
CRFs will be designed and monitored by the Medidata
Rave™ representatives in the Data Management Core at
Cincinnati Children’s Hospital Medical Center (CCHMC).
As the project coordinators, the Center for Acute Care
Nephrology (CACN) at CCHMC will be the only site that
can access the data from all other sites. Other sites will
have access only to their enrolled subjects. Data manage-
ment and statistical analysis will be executed at CCHMC.
The AWARE study is a featured study of the Prospective
Pediatric Acute Kidney Injury Registry (www.ppaki.org).
Founded in 2012, the ppAKI is an international research
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intensivists striving to foster development and advances in
the research of pediatric acute kidney injury.
Discussion
The global epidemiology of pediatric acute kidney injury
is unknown. What is known is that the landscape of
pediatric AKI is dynamic, changing considerably in the
past 30 years, from a name change (acute renal failure to
acute kidney injury), to continual reclassification (RIFLE,
pRIFLE, AKIN, and KDIGO), to a growing appreciation
of disease severity and associated disease burden. Novel
diagnostic methodologies including renal angina and
urinary biomarkers are expected to advance the field of
AKI diagnostics. Unfortunately, contrasted with large scale
adult epidemiologic studies, robust and broad based data
in pediatrics is currently unavailable. The paucity of in-
clusive and expansive pediatric data presents a major
hurdle to the advancement of the field towards improving
outcomes.
Strengths in the design of this prospective trial include
the magnitude of patient enrollment (over 5,000 expected
and at the time of this writing over 3,500 enrolled), the
broad geographic distribution of patients (from over 5
continents and a site in South Africa still pending site in-
stitutional review board approval), and the inclusion of all
ICU patients – regardless of previously documented AKI
risk factors (i.e. sepsis, mechanical ventilation, cardiopul-
monary bypass). The repository of data collected will in-
form critical care nephrologists for many years to come
and allow for analysis of many epidemiologic AKI associa-
tions and refinement of renal angina for AKI prediction
and classification. The capture of urine for biomarker ana-
lysis also represents the largest urine biobank repository
in pediatric critical care to date for the study of AKI.
Given the expected population size and data to be pro-
spectively captured, the AWARE study will facilitate ana-
lysis of many questions surrounding AKI, both diagnostic
and therapeutic. A few examples of targeted questions po-
tentially answerable by mining the database include: a) the
association of resuscitative fluids and AKI, b) delineation
of predictive and associated factors between transient ver-
sus persistent AKI, c) the independent outcomes of fluid
overload and oliguria in all critically ill patients, and the
d) associations and outcomes of subclinical-AKI.
The design of this prospective study has limitations. We
make several assumptions with regards to the expected
incidence of AKI per PICU/CICU center. Differing geo-
graphic areas included in our enrollment study list and
different patient demographics may have greater or less
incidence of AKI risk. Many pediatric patients have no
‘baseline’ creatinine measured prior to the time of acute
illness. Our assumption of a normal creatinine clearance
is based on the use of this paradigm in previous study [4].Additionally, we assume that 33% or greater of our enroll-
ment sites will be able to capture urine for the biomarker
analysis. Perhaps the greatest limitation is that this study
is being independent of financial reimbursement. Study
coordinators, research coordinators, and data manage-
ment specialists at each site are not compensated for the
exclusive purpose of this study, which has the potential to
bias the enrollment strength of each center (depending on
staff enthusiasm and availability). All of these limitations
can also be interpreted as strengths of the study, however.
Our initial results indicate that the AWARE study will as-
semble a broad and heterogeneous patient repository and
that the pro bono work done by our coordinating sites is
robust. It is our expectation that the AWARE study will
serve as a model, a proof of concept that resources are in
place to facilitate broad based pediatric AKI studies, for
future large scale multicenter studies that are funded and
sponsored by governmental and private financial support.
AKI is a significant disease syndrome affecting a large
proportion of pediatric ICU patients. Existing data indi-
cates that patients are not just dying with AKI, but from
AKI [35]. AWARE is a first of its kind and vital study of
critically ill children that will inform the pediatric critical
care nephrology community of the prevalence and asso-
ciations of AKI across the globe, offering new perspec-
tives for prediction and detection of disease.
Trial status
Recruitment is currently active at most centers, but is lim-
ited to three consecutive months from the time of initi-
ation at each center. Patient enrollment and data capture
is expected to be complete by January 1, 2015.Additional files
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AWARE study sites.
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